NEW YORK – Proteomics firm Nautilus Biotechnology plans to list on the Nasdaq through a merger with special purpose acquisition company Arya Sciences Acquisition Corp III.
Seattle-based Nautilus has entered a definitive merger agreement with Arya and is expected to receive $350 million in proceeds through the deal, including a $200 million private investment in public equity (PIPE) transaction at $10 per share from investors led by Perceptive Advisors, an affiliate of Arya III's sponsor.